Skip to main content
رجوع
PEN logo

Penumbra, Inc.

جودة البيانات: 100%
PEN
NYSE Healthcare Medical - Devices
KWD 336.27
▲ KWD 2.10 (0.63%)
القيمة السوقية: 13.20B
نطاق اليوم
KWD 335.06 KWD 336.68
نطاق 52 أسبوعًا
KWD 221.26 KWD 362.41
حجم التداول
262,377
متوسط 50 يوم / 200 يوم
KWD 341.27 / KWD 283.75
الإغلاق السابق
KWD 334.17

Quick Summary

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (631 نظير)

المقياس السهم وسيط القطاع
P/E 74.3 0.2
P/B 9.2 3.0
ROE % 13.8 3.6
Net Margin % 12.7 3.8
Rev Growth 5Y % 17.1 10.0
D/E 0.2 0.2

السعر المستهدف للمحللين

Hold
KWD 371.92 +10.6%
Low: KWD 349.00 High: KWD 388.00
مكرر الربحية المستقبلي
66.97
ربحية السهم المستقبلية
KWD 5.02
نمو ربحية السهم (تقدير)
+0.0%
الإيرادات المقدّرة
1.59B

تقديرات الأرباح

الفترة تقدير ربحية السهم تقدير الإيرادات المحللون
FY2029 KWD 9.25
KWD 8.93 – KWD 9.57
 2.26B 2
FY2028 KWD 7.60
KWD 7.03 – KWD 8.91
 2.04B 4
FY2027 KWD 6.37
KWD 5.47 – KWD 6.90
 1.80B 11

Earnings Surprises

Last 8 quarters
Quarter Est. EPS Actual EPS Surprise
2026-02-25 KWD 1.11 KWD 1.18 +6.3%
2025-11-05 KWD 0.93 KWD 0.97 +4.4%
2025-07-29 KWD 0.81 KWD 0.86 +6.2%
2025-04-23 KWD 0.66 KWD 0.83 +25.8%
2025-02-18 KWD 0.88 KWD 0.97 +10.2%
2024-10-30 KWD 0.69 KWD 0.85 +23.2%
2024-07-30 KWD 0.56 KWD 0.64 +14.3%
2024-05-07 KWD 0.42 KWD 0.41 -2.4%

Dividend History

Yield

0.00%

Payout Ratio

0.00%

Growth (3Y)

N/A

Growth (5Y)

N/A

No dividend history available.

النقاط الرئيسية

Revenue grew 17.06% annually over 5 years — strong growth
Earnings grew 1168.11% over the past year
ROE of 13.78% — decent returns on equity
Debt/Equity of 0.15 — conservative balance sheet
Generating 174.93M in free cash flow
P/E of 74.27 — premium valuation

النمو

Revenue Growth (5Y)
17.06%
Revenue (1Y)17.50%
Earnings (1Y)1168.11%
FCF Growth (3Y)45.95%

الجودة

Return on Equity
13.78%
ROIC8.62%
Net Margin12.66%
Op. Margin13.48%

الأمان

Debt / Equity
0.15
Current Ratio6.64
Interest Coverage0.00

التقييم

P/E Ratio
74.27
Forward P/E66.97
P/B Ratio9.24
EV/EBITDA69.90
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 17.50% Revenue Growth (3Y) 15.15%
Earnings Growth (1Y) 1168.11% Earnings Growth (3Y) 39.77%
Revenue Growth (5Y) 17.06% Earnings Growth (5Y) 140.81%
Profitability
Revenue (TTM) 1.40B Net Income (TTM) 177.69M
ROE 13.78% ROA 9.73%
Gross Margin 67.14% Operating Margin 13.48%
Net Margin 12.66% Free Cash Flow (TTM) 174.93M
ROIC 8.62% FCF Growth (3Y) 45.95%
Safety
Debt / Equity 0.15 Current Ratio 6.64
Interest Coverage 0.00
Dividends
Dividend Yield 0.00% Payout Ratio 0.00%
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio 74.27 Forward P/E 66.97
P/B Ratio 9.24 P/S Ratio 9.40
PEG Ratio 0.06 Forward PEG N/A
EV/EBITDA 69.90 Fwd EV/EBITDA 120.65
Forward P/S 8.32 Fwd Earnings Yield 1.49%
FCF Yield 1.33%
Market Cap 13.20B Enterprise Value 13.23B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 1.40B 1.19B 1.06B 847.13M 747.59M
Net Income 177.69M 14.01M 90.95M -2.00M 5.28M
EPS (Diluted) 4.52 0.36 2.32 -0.05 0.14
Gross Profit 942.44M 755.00M 682.64M 535.21M 475.38M
Operating Income 189.25M 9.28M 73.55M 6.08M -7.50M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 1.83B 1.53B 1.56B 1.37B 1.24B
Total Liabilities 398.92M 382.25M 377.36M 372.03M 290.32M
Shareholders' Equity 1.43B 1.15B 1.18B 998.86M 953.93M
Total Debt 219.70M 223.39M 234.34M 235.77M 173.55M
Cash & Equivalents 186.90M 324.40M 167.49M 69.86M 59.38M
Current Assets 1.22B 951.13M 915.40M 755.70M 681.47M
Current Liabilities 183.13M 158.35M 151.14M 144.93M 123.20M